Loss of visual acuity under dopamine substitution therapy

References

• Braak H, Braak E, Yilmazer D, Schultz C, de Vos RA, Jansen EN. Nigral and extranigral pathology in Parkinson�s disease. J Neural Transm Suppl 1995;46:15–31.
   Google Scholar
• Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J. Pattern of brain destruction in Parkinson�s and Alzheimer�s disease. J Neural Transm 1996;103(4):455–490.
   Google Scholar
• Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J. Neurofibrillary tangles and neuropil threads as a cause of dementia in Parkinson�s disease. J Neural Transm Suppl 1997; 51:49–55.
   Google Scholar
• Braak H, Sandmann-Keil D, Gai W, Braak E. Extensive axonal Lewy neurites in Parkinson�s disease: a novel pathological feature revealed by alpha-synuclein immunohistochemistry. Neurosci Lett 1999;265(1):67–69.
   PubMed Web of Science ®Google Scholar
• Foley P, Riederer P. Pathogenesis and preclinical course of Parkinson�s disease. J Neural Transm Suppl 1999; 56:31–74.
   PubMedGoogle Scholar
• Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson� disease. Invest Ophthalmol Vis Sci 1990;31(11): 2473–2475.
   Web of Science ®Google Scholar
• Masson G, Mestre D, Blino. Dopaminergic modulation of visual sensitivity in man. Fundam Clin Pharmacol 1993;7(8):449–463.
   Google Scholar
• Nguyen-Legros J. Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson�s disease. Surg Radiol Anat 1988;10(2):137–144.
   PubMed Web of Science ®Google Scholar
• Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson�s disease patients. Trends Neurosci 1990;13(7):296–302.
   Google Scholar
• Djamgoz MB, Hankins MW, Hirano J, Archer SN. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res 1997; 37(24):3509–3529.
   PubMed Web of Science ®Google Scholar
• Ikeda H, Head GM, Ellis CJ. Electrophysiological signs of retinal dopamine deficiency in recently diagnosed Parkinson�s disease and a follow up study. Vision Res 1994; 34(19):2629–2638.
   Google Scholar
• Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson�s disease. Neurology 1992; 42(4):887–890.
   PubMed Web of Science ®Google Scholar
• Ghilardi MF, Chung E, Bodis-Wollner I, Dvorzniak M, Glover A, Onofrj M. Systemic 1-methyl, 4-phenyl, 1-2-3-6- tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates. Life Sci 1988;43(3):255–262.
   Google Scholar
• Barbato L, Rinalduzzi S, Laurenti M, Ruggieri S, Accornero N. Color VEPs in Parkinson�s disease. Electorencephalogr Clin Neurophysiol 1994;92(2): 169–172.
   Google Scholar
• B�ttner T, Kuhn W, Patzold T, Przuntek H. L-Dopa improves colour vision in Parkinson�s disease. J Neural Transm Park Dis Dement Sect 1994; 7(1):13–19.
   Google Scholar
• Bulens C, Meerwaldt JD, Van der Wildt GJ, Van Deursen JB. Effect of levodopa treatment on contrast sensitivity in Parkinson�s disease. Ann Neurol 1987;22(3):365–369.
   Google Scholar
• Peppe A, Stanzione P, Pierantozzi M, Semprini R, Bassi A, Santilli AM, Formisamo R, Piccolino M, Bernardi G. Does pattern electroretinogram spatial tuning alteration in Parkinson�s disease depend on motor disturbances or retinal dopaminergic loss? Electorencephalogr Clin Neurophysiol 1998;106(4):374–382.
   Google Scholar
• Stanzione P, Traversa R, Pierantozzi M, Semprini R, Marciani MG, Bernardi G. An electrophysiological study of D2 dopaminergic actions in normal human retina: a tool in Parkinson�s disease. Neurosci Lett 1992;140(1):125–128.
   Google Scholar
• Stanzione P, Bodis-Wollner I, Pierantozzi M, Semprini R, Tagliati M, Peppe A, Bernardi G. A mixed D1 and D2 antagonist does not replay pattern electroretinogram alterations observed with a selective D2 antagonist in normal humans: relationship with Parkinson�s disease pattern electroretinogram recordings. Clin Neurophysiol 1999;110(1):82–85.
   Google Scholar
• Dubocovich ML, Weiner N. Pharmacological differences between the D-2 autoreceptor and the D-1 dopamine receptor in rabbit retina. J Pharmacol Exp Ther 1985;233(3):747–754.
   Google Scholar
• M�ller T, Eising EG, Reiers C, Przuntek H, Jacob M, Kuhn W. 2- [123I]-Iodolisuride SPET visualizes dopaminergic loss in de novo parkinsonian patients: is it a marker of striatal pre-synaptic degeneration? Nucl Med Commun 1997;18: 1115–1121.
   Google Scholar
• Nisoli E, Tonello C, Memo M, et al. Tolerance to hypoactivity and sensitization to hyperactivity after chronic treatment with a presynaptic dose of lisuride in rats. Eur J Pharmacol 1992;216:81–86.
   Google Scholar
• Skirrboll LR, Gracia AA, Bunney BS. Dopamine auto- and postsynaptic receptors: electrophysiological evidence for differential sensitivity to dopamine agonists. Science 1979;206: 80–82.
   Google Scholar
• Tissari AH, Gessa GL. Ergot induced inhibition of dopamine synthesis in striatal synaptosomes: a D2 receptor mediated mechanism. In: Calne DB, McDonald RJ, Horowski R, Wuttke W, editors. Lisuride and Other Dopamine Agonists: Basic Mechanisms and Endocrine and Neurological Effects. New York: Raven Press, 1983; 33–44.
   Google Scholar
• Tissari AH, Lillgals MS. Reduction of dopamine synthesis inhibition by dopamine autoreceptor activation in striatal synaptosomes with in vivo reserpine administration. J Neurochem 1993;61:231–228.
   Google Scholar